211 related articles for article (PubMed ID: 23909993)
1. Adalimumab for the treatment of psoriasis in real life: a retrospective cohort of 119 patients at a single Spanish centre.
López-Ferrer A; Vilarrasa E; Gich IJ; Puig L
Br J Dermatol; 2013 Nov; 169(5):1141-7. PubMed ID: 23909993
[TBL] [Abstract][Full Text] [Related]
2. Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.
van Lümig PP; van de Kerkhof PC; Boezeman JB; Driessen RJ; de Jong EM
J Eur Acad Dermatol Venereol; 2013 May; 27(5):593-600. PubMed ID: 22416818
[TBL] [Abstract][Full Text] [Related]
3. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
4. Adalimumab treatment for severe recalcitrant chronic plaque psoriasis.
Ryan C; Kirby B; Collins P; Rogers S
Clin Exp Dermatol; 2009 Oct; 34(7):784-8. PubMed ID: 19438535
[TBL] [Abstract][Full Text] [Related]
5. Impact of obesity on the effectiveness of adalimumab for the treatment of psoriasis: a retrospective study of 30 patients in daily practice.
Lafuente-Urrez RF; Pérez-Pelegay J
Eur J Dermatol; 2014; 24(2):217-23. PubMed ID: 24721290
[TBL] [Abstract][Full Text] [Related]
6. Infliximab for the treatment of psoriasis in Greece: 4 years of clinical experience at a single centre.
Antoniou C; Stefanaki I; Stratigos A; Moustou E; Vergou T; Stavropoulos P; Avgerinou G; Rigopoulos D; Katsambas AD
Br J Dermatol; 2010 May; 162(5):1117-23. PubMed ID: 19906069
[TBL] [Abstract][Full Text] [Related]
7. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
8. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis.
Menter A; Gordon KB; Leonardi CL; Gu Y; Goldblum OM
J Am Acad Dermatol; 2010 Sep; 63(3):448-56. PubMed ID: 20605254
[TBL] [Abstract][Full Text] [Related]
10. Adalimumab for psoriasis in Greece: clinical experience in a tertiary referral centre.
Fotiadou C; Lazaridou E; Sotiriou E; Ioannides D
J Eur Acad Dermatol Venereol; 2012 Oct; 26(10):1298-303. PubMed ID: 21967627
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb study.
Papp K; Ho V; Teixeira HD; Guerette B; Chen K; Lynde C
J Eur Acad Dermatol Venereol; 2012 Aug; 26(8):1007-13. PubMed ID: 22023702
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.
Inzinger M; Heschl B; Weger W; Hofer A; Legat FJ; Gruber-Wackernagel A; Tilz H; Salmhofer W; Quehenberger F; Wolf P
Br J Dermatol; 2011 Sep; 165(3):640-5. PubMed ID: 21564068
[TBL] [Abstract][Full Text] [Related]
14. Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.
Gniadecki R; Bang B; Bryld LE; Iversen L; Lasthein S; Skov L
Br J Dermatol; 2015 Jan; 172(1):244-52. PubMed ID: 25132294
[TBL] [Abstract][Full Text] [Related]
15. Analysis of body regions and components of PASI scores during adalimumab or methotrexate treatment for patients with moderate-to-severe psoriasis.
Navarini AA; Poulin Y; Menter A; Gu Y; Teixeira HD
J Drugs Dermatol; 2014 May; 13(5):554-62. PubMed ID: 24809878
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy, safety and drug survival of ustekinumab in a Spanish cohort of patients with moderate to severe plaque psoriasis.
Puig L; Ruiz-Salas V
Dermatology; 2015; 230(1):46-54. PubMed ID: 25572820
[TBL] [Abstract][Full Text] [Related]
17. Treatment of severe, recalcitrant, chronic plaque psoriasis with fumaric acid esters: a prospective study.
Wain EM; Darling MI; Pleass RD; Barker JN; Smith CH
Br J Dermatol; 2010 Feb; 162(2):427-34. PubMed ID: 19519838
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of adalimumab in the treatment of psoriasis: a retrospective study of 15 patients in daily practice.
Sola-Ortigosa J; Sánchez-Regaña M; Umbert-Millet P
J Dermatolog Treat; 2012 Jun; 23(3):203-7. PubMed ID: 21787203
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study.
Leonardi C; Sobell JM; Crowley JJ; Mrowietz U; Bao Y; Mulani PM; Gu Y; Okun MM
Br J Dermatol; 2012 Sep; 167(3):658-67. PubMed ID: 22564148
[TBL] [Abstract][Full Text] [Related]
20. Treatment effect of adalimumab and infliximab in Japanese psoriasis patients: results in a single community-based hospital.
Noda S; Mizuno K; Adachi M
J Dermatol; 2012 Mar; 39(3):265-8. PubMed ID: 22126280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]